Navigation Links
12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis
Date:8/19/2008

SYDNEY, Australia, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the Phase 3 clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no serious adverse events attributed to the drug following 12 months of treatment.

A total of 123 subjects started treatment with 320 mg Bronchitol twice per day and 99 subjects completed the full 12 months of the trial. Of the 24 withdrawals, only seven were a result of adverse events (three related to lung infections and two related to cough).

The most common adverse events attributed to treatment were cough in 9% of the subjects and sore throat in 5%. Other reported adverse events related to treatment were infrequent, mild in severity and in most cases were a consequence of the underlying disease.

Pharmaxis CEO Alan Robertson said: "Pharmaxis intends to file a marketing application in Australia for Bronchitol as soon as possible now that this study has concluded satisfactorily.

"Bronchitol has created a great deal of interest among people suffering with bronchiectasis and we continue to respond to requests from trial participants and others interested in Bronchitol. We are looking forward to bringing Bronchitol to the market place and are delighted this trial has concluded successfully."

This 12 month treatment period was an open label extension to a three month efficacy trial which reported in the second half of 2007.

The conclusion from this trial is that Bronchitol improves quality of life and mucus clearance following three months of treatment and is safe and well tolerated following 12 months of treatment. The open label component of the trial reported today supports the efficacy reported earlier in the blinded phase of the trial.

Bronchitol is being initially developed as a twice daily inhalation therapy for people with the incurable lung condi
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
6. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
7. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
8. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
9. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
10. Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 This study provides ... imaging informatics solutions including nuclear imaging informatics, PET ... The study assesses the size of the market ... 2013, and projects future growth based on the ... dynamics taking place in the broader markets for ...
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
(Date:10/1/2014)... Bedros Keuilian is not only the ... boot camps, he’s also considered the leading expert on ... out business summits, a line of high-demand fitness marketing ... recent Spike TV reality show to his name. , ... time for personal trainers and fitness business owners to ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Phoseon Technology, ... , continues to expand the business worldwide. This rapid ... with additional capacity for manufacturing efforts. The company has ... last five years and expects this growth to continue ... curing technology gains worldwide adoption. , “We are ...
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... Inc., announced today their new NoteSwift™ 2.0 for Allscripts ... the bridge between the EHR and Dragon Medical interpreting ... at the point of care. NoteSwift reduces the time ... than half – and virtually eliminates mouse clicks – ... EHR use according to the June 12, 2014 HIMSS ...
Breaking Medicine News(10 mins):Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3
... levels of hostility have a greater risk of heart disease ... the US conducted a survey of 720 men, average age ... world around them.// They also asked them about traditional heart ... hip ratio. ,They found that among the men ...
... researchers, high blood pressure is a major factor accounting ... It's well known that black people live, on average, ... did not complete //high school are at a similar ... first time, a study has identified the major health ...
... recent study that women who are obese in middle age ... marked to the carotid arteries// in the neck as a ... the heart. If the linings of the carotid arteries are ... heart disease. ,In a new study, doctors in ...
... study shows there is no conclusive medical reason, based on ... become pregnant by in vitro fertilization. Researchers from the Keck ... pregnancy outcomes in women, ages 50 and older, who conceived ... cases of 70 post menopausal women with no chronic medical ...
... According to pre-clinical study it is observed that it ... the bloodstream of a patient with suppressed immunity, sepsis ... fateful. And treatment with antibiotics is often ineffective. ... have been looking at a vaccine for sepsis. It ...
... According to a major medical study by researchers it ... benefits. The latest from researchers in Denmark, observe that ... a lesser risk of developing dementia and Alzheimer's disease. ... most benefit. ,The researchers are realistic about their ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: